Clinical Trial Update: Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) [Phase 3]

View source ↗

Summary

Phase 3 study comparing Xaluritamig with cabazitaxel or a second androgen receptor-directed therapy in progressive metastatic castration-resistant prostate canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Jevtana (cabazitaxel)
• Xaluritamig (Xaluritamig)

Snippet

Sponsor: Amgen | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 3 | Status: RECRUITING